5th Floor, 56, Nonhyeon-ro 67-gil
Standigm is a company to apply cutting-edge AI technologies to drug discovery and development. Standigm focuses on predicting new indications for existing drugs, called drug repositioning through the deeply trained AI model with molecular features of drug responses and drug uses. Standigm generated tens of drug candidates for cancers, Parkinson's disease (PD), autism, fatty liver diseases (NASH) and more. Standigm was found in May 2015 by cofounders from Samsung Advanced Institute of Technology. Standigm has raised $3.4M.
Founders: Jinhan Kim, Sang Ok Song, and So Jeong Yun
Founder and CEO: Jinhan Kim
Founder and COO: Sang Ok Song
Founder and CRO: So Jeong Yun
2 articles with Standigm
Standigm Raises US $11.5 Million in Series B Round Funding to Advance its AI-powered Drug Pipelines toward License-out.
Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced it has raised $11.5 million in a Series B funding round led by Mirae Asset Venture Investment and Mirae Asset Capital.
Standigm, an AI Based Drug Discovery Company, Launched AI Drug Discovery Services Publicly at Bio-Europe 2017 in Berlin, Germany
Bio-Europe is the Europe's largest partnering conference for the biotechnology industry.